^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Esophageal Adenocarcinoma

    Related cancers:
    2d
    A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=37 --> 20
    Enrollment closed • Enrollment change
    |
    paclitaxel • Cyramza (ramucirumab) • balstilimab (AGEN2034) • botensilimab (AGEN1181) • AgenT-797
    4d
    KEYNOTE 975: Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) (clinicaltrials.gov)
    P3, N=703, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2027 --> Jun 2026 | Trial primary completion date: Feb 2027 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cisplatin • 5-fluorouracil • oxaliplatin • levoleucovorin calcium
    6d
    Individually Tailored, Supervised, Remote Exercise Intervention to Improve Physical Function for Stage I-III Gastroesophageal Cancer Survivors, PRECISE Trial (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Mar 2028 --> Sep 2028 | Initiation date: Mar 2026 --> Sep 2026 | Trial primary completion date: Mar 2027 --> Sep 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    7d
    A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States (clinicaltrials.gov)
    P2, N=30, Recruiting, BeOne Medicines | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • leucovorin calcium
    7d
    Single-cell and bulk omics uncover fibroblast heterogeneity and HSPH1 as a key driver in Barrett's esophagus to esophageal adenocarcinoma progression. (PubMed, Cancer Cell Int)
    Our study reveals critical fibroblast-epithelial interactions in NC-BE-EAC progression and identifies HSPH1 as a potential biomarker and therapeutic target. These findings may facilitate risk stratification and personalized treatment strategies for EAC.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • SDC1 (Syndecan 1) • COL1A1 (Collagen Type I Alpha 1 Chain) • HSPH1 (Heat Shock Protein Family H (Hsp110) Member 1) • ITGA2 (Integrin Subunit Alpha 2) • ITGB1 (Integrin Subunit Beta 1)
    7d
    ZANGEA: Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients (clinicaltrials.gov)
    P2, N=80, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 positive
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • Ziihera (zanidatamab-hrii)
    7d
    GEMINI-PeriOp GC: A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=100, Recruiting, AstraZeneca
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 positive • HER-2 negative • CLDN18.2 positive • CLDN18.2 positive + HER-2 negative
    |
    docetaxel • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936)
    9d
    IKS014-01: IKS014 in Advanced Solid Tumors That Express HER2 (clinicaltrials.gov)
    P1, N=165, Recruiting, Iksuda Therapeutics Ltd. | Trial completion date: Sep 2027 --> Dec 2027 | Trial primary completion date: Sep 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 positive • HR positive • HER-2 amplification • HER-2 expression • HER-2 amplification + HR-positive
    |
    caxmotabart entudotin (IKS014)
    11d
    SOS6C: Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma (clinicaltrials.gov)
    P=N/A, N=450, Enrolling by invitation, Mayo Clinic | N=300 --> 450
    Enrollment change • Grant
    11d
    ROSETTA GI 204: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) (clinicaltrials.gov)
    P2/3, N=690, Recruiting, Bristol-Myers Squibb
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • 5-fluorouracil • pumitamig (BNT327)
    12d
    Targeting overexpressed oncogenes in esophageal cancer through miRNA-mediated gene silencing: Insights from binding affinity and thermodynamic profiling. (PubMed, Mutat Res)
    TCGA-based validation showed that only a subset of predicted interactions is functionally relevant, with hsa-miR-30d-5p exhibiting a significant inverse correlation with CHST2. These findings highlight the importance of integrating predictive and expression data to identify biologically meaningful miRNA-mRNA interactions in esophageal cancer.
    Journal
    |
    MIR30D (MicroRNA 30d)
    13d
    Targeting DOT1L Reactivates HERV-K to Drive Cell Autonomous and Paracrine Senescence in Adenocarcinoma of the Esophagogastric Junction. (PubMed, Cancer Res)
    By promoting the assembly and secretion of HERV-K-derived retrovirus-like particles (RVLPs), DOT1L inhibition propagated senescence to neighboring tumor cells via STING pathway activation. Together, this study not only establishes DOT1L as a druggable epigenetic target in AEG but also proposes a therapeutic strategy that leverages HERV-K and RVLPs to drive tumor cell senescence and intercellular senescence transmission for antitumor therapy.
    Journal
    |
    DOT1L (DOT1 Like Histone Lysine Methyltransferase)